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Abstract. A hypermethylation defect associated with DNMT 
hyperactivity and DNMT3b overexpression characterizes a 
subset of breast cancers and breast cancer cell lines. We analyzed 
breast cancer cell lines for differential expression of regulatory 
miRs to determine if loss of miR-mediated post-transcriptional 
regulation of DNMT3b represents the molecular mechanism that 
governs the overexpression of DNMT3b that drives the hyper-
methylation defect in breast cancer. MicroRNAs (miRs) that 
regulate (miR-29a, miR-29b, miR-29c, miR-148a, miR-148b) or 
are predicted (miR-26a, miR-26b, miR-203, miR-222) to regu-
late DNMT3b were examined among 10 hypermethylator and 6 
non-hypermethylator breast cancer cell lines. Hypermethylator 
cell lines express diminished levels of miR-29c, miR-148a, 
miR-148b, miR-26a, miR-26b, and miR-203 compared to non-
hypermethylator cell lines. miR expression patterns correlate 
inversely with methylation-sensitive gene expression (r=-0.66, 
p=0.0056) and directly with the methylation status of these genes 
(r=0.72, p=0.002). To determine the mechanistic role of specific 
miRs in the dysregulation of DNMT3b among breast cancer cell 
lines, miR levels were modulated by transfection of pre-miR 
precursors for miR-148b, miR-26b, and miR-29c into hypermeth-
ylator cell lines (Hs578T, HCC1937, SUM185) and transfection 
of antagomirs directed against miR-148b, miR-26b, and miR-29c 
into non-hypermethylator cell lines (BT20, MDA-MB-415, 
MDA-MB-468). Antagomir-mediated knock-down of miR-
148b, miR-29c, and miR-26b significantly increased DNMT3b 
mRNA in non-hypermethylator cell lines, and re-expression of 
miR-148b, miR-29c, and miR-26b following transfection of 
pre-miR precursors significantly reduced DNMT3b mRNA in 
hypermethylator cell lines. These findings strongly suggest that: 
i) post-transcriptional regulation of DNMT3b is combinatorial, 
ii) diminished expression of regulatory miRs contributes to 
DNMT3b overexpression, iii) re-expression of regulatory miRs 
reduces DNMT3b mRNA levels in hypermethylator breast cancer 
cell lines, and iv) down-regulation of regulatory miRs increases 
DNMT3b mRNA levels in non-hypermethylator breast cancer 
cell lines. In conlcusion, the molecular mechanism governing 
the DNMT3b-mediated hypermethylation defect in breast cancer 
cell lines involves the loss of post-transcriptional regulation of 
DNMT3b by regulatory miRs.
Introduction
Aberrant DNA methylation and epigenetic silencing of gene 
expression are well recognized hallmarks of cancer (1,2), and 
methylation-dependent gene silencing occurs frequently in breast 
cancer (3-6). Changes in gene expression patterns secondary to 
methylation-dependent gene silencing fundamentally contribute 
to initiation, development, and progression of breast cancer (7-9). 
We identified a novel hypermethylation defect that is expressed 
in a subset of breast cancer cell lines and is characterized by 
epigenetic silencing of methylation-sensitive genes secondary to 
overexpression of DNMT3b and DNA methyltransferase hyper-
activity (10). The hypermethylation defect observed among breast 
cancer cell lines is associated with a characteristic gene expres-
sion signature that reflects methylation-dependent silencing 
of a panel of epigenetic biomarker genes (including CDH1, 
CEACAM6, CST6, ESR1, GNA11, MUC1, MYB, SCNN1A and 
TFF3) (10). This hypermethylation gene signature was established 
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in human breast cancer cell lines, but also identifies a subset of 
primary sporadic breast cancers (10). A robust correspondence is 
observed between the expression of the hypermethylation defect 
and the basal-like molecular subtype of breast cancer, suggesting 
that this may be a defining characteristic of this breast cancer 
subtype (10). However, the molecular mechanism that governs 
the overexpression of DNMT3b among hypermethylator breast 
cancer cell lines has not been investigated.
DNMT3b is constitutively expressed by all mammalian 
cell types, but is frequently overexpressed in cancer (11-14). 
However, unlike other genes that are overexpressed in cancer, 
the mechanisms accounting for increased DNMT3b levels 
infrequently involve gene mutations and/or gene amplifica-
tion (15). Likewise, increased DNMT3b transcription due to 
increased trans-activation does not commonly occur in cancer 
(15). Rather, it is now recognized that DNMT3b is subject to 
post-transcriptional regulation by microRNAs (miRs), which are 
small non-coding RNAs (19-25 nucleotide long) that regulate 
gene expression through sequence-specific targeting of mRNAs, 
producing either translational repression or degradation of the 
target mRNA (16,17). miRs are expressed in a tissue-specific 
manner and have been implicated in the regulation of several 
biological processes, including cellular proliferation, apoptosis, 
and development (18-21). Altered miR expression is associated 
with several types of human cancer, including breast cancer 
(22-25). Recent studies have identified miRs as both regulators of 
DNA methyltransferase (DNMT) expression and targets of aber-
rant DNA methylation in various tissue types. The miR-29 family 
(miR-29a, miR-29b, miR-29c) directly targets DNMT3a and 
DNMT3b in lung cancer (26) and acute myeloid leukemia (27). 
Likewise, the miR-148 family (miR-148a, miR-148b) regulates 
DNMT3b in cell lines of multiple origin, including the MCF-7 
breast cancer cell line (28). In human bladder cancer, miR-127 is 
silenced by promoter hypermethylation (29). In similar fashion, 
miR-148a is epigenetically silenced in human cancer cell lines 
established from lymph node metastasis from colon, melanoma, 
and head/neck, suggesting that epigenetic loss of miR-148 is 
associated with progressive changes such as development of 
metastatic potential (24). All of these observations indicate direct 
interactions as well as cross-talk between the DNA methylation 
machinery and miRs.
In the present study, we analyzed breast cancer cell lines for 
differential expression of regulatory miRs to determine if loss 
of miR-mediated post-transcriptional regulation of DNMT3b 
represents the molecular mechanism that governs the overex-
pression of DNMT3b which drives the hypermethylation defect 
in breast cancer. The results show that multiple miRs (miR-29c, 
miR-148a, miR-148b, miR-26a, miR-26b, and miR-203) post-
transcriptionally regulate DNMT3b in combination and loss of 
expression of these regulatory miRs contributes to DNMT3b 
overexpression in hypermethylator cell lines. We also observed 
that enforced expression of regulatory miRs results in reduced 
DNMT3b mRNA levels in hypermethylator breast cancer cell 
lines, and that down-regulation of regulatory miRs results in 
increased DNMT3b mRNA levels in non-hypermethylator 
breast cancer cell lines. These observations combine to suggest 
that the loss of multiple regulatory miRs that post-transcrip-
tionally regulate DNMT3b levels is involved in the molecular 
mechanism governing the DNMT3b-mediated hypermethyl-
ation defect in breast cancer cell lines.
Materials and methods
Cell lines and growth conditions. Human breast cancer cell lines 
BT20 (ATCC no.  HTB19), BT549 (HTB122), Hs578T (HTB126), 
MCF7 (HTB22), MDA-MB-231 (HTB26), MDA-MB-415 
(HTB128), MDA-MB-435S (HTB129), MDA-MB-436 
(HTB130), MDA-MB-453 (HTB131), MDA-MB-468 
(HTB132), SKBR3 (HTB30), and ZR-75-1 (CRL-1500) were 
obtained from the Tissue Culture Core Facility of the University 
of North Carolina Lineberger Comprehensive Cancer Center 
(Chapel Hill, NC). Human breast cancer cell lines SUM102, 
SUM149, and SUM185 were a gift from the laboratories of Dr 
Carolyn I. Sartor (Department of Radiation Oncology, UNC 
School of Medicine, Chapel Hill, NC) and Dr Stephen Ethier 
(Department of Pathology, Wayne State University School of 
Medicine, Detroit, MI). Human breast cancer cell line HCC1937 
(CRL-2336) was a gift from the laboratory of Dr William K. 
Kaufmann (Department of Pathology and Laboratory Medicine, 
UNC School of Medicine). The normal breast epithelial cell 
line MCF12A (CRL-10782) was obtained from the ATCC 
(American Type Culture Collection, http://www.atcc.org/). Cell 
lines were propagated in growth medium recommended by the 
ATCC, except for SUM102, SUM149, and SUM185 cells which 
were cultured in 1:1 mixture of Dulbecco's modified Eagle's 
medium and Ham's F12 (DMEM/F12, Gibco/Invitrogen Life 
Technologies, Carlsbad, CA) medium supplemented with 10% 
horse serum (Gibco/Invitrogen Life Technologies), and 1% 
antibiotic-antimycotic (Gibco/Invitrogen Life Technologies). 
Growth medium was refreshed three times weekly unless other-
wise specified for antagomir and pre-miR transfections. Cells 
were maintained at 37˚C and 5% CO2 (except for MDA-MB-468 
which was propagated in 100% atmospheric air).
RNA extraction for gene expression analysis. Total RNA for gene 
expression analysis and miR expression analysis was isolated 
from breast cancer cell lines, MCF12A (normal mammary 
epithelial cell line), and transfected cell lines (antagomir or 
pre-miR transfected) utilizing the method of Chomczynski 
and Sacchi (30), modified for TRIzol Reagent (Invitrogen Life 
Technologies, Carlsbad, CA), according to the manufacturer's 
protocol. Nucleic acid samples were DNAse (Cat no. M610A; 
Promega, Madison, WI) treated (0.02 U/µl at 37˚C for 30 min), 
and purified using the Qiagen RNeasy mini-kit (Cat no. 74104; 
Qiagen, Valencia, CA). Isolated RNA was quantified after 
extraction using a Nanodrop Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE).
MicroRNA expression analysis. DNMT3b is subject to miR-
mediated post-translational regulation. The miR-29 family 
(miR-29a, miR-29b, miR-29c) has been implicated in DNMT3b 
dysregulation in lung cancer (26) and acute myeloid leukemia 
(27), and the miR-148 family (miR-148a, miR-148b) has been 
implicated in DNMT3b dysregulation in cell lines of multiple 
origins, including the MCF-7 breast cancer cell line (28). We 
identified candidate miRs as potential regulators of DNMT3b 
using the computational tools of target prediction programs 
and resources from publicly available databases, including 
Miranda (http://www.microRNA.org/), TargetScan (http://www.
targetscan.org/vert_42/), miRGen (http://www.diana.pcbi.upenn.
edu/miRGen/v3/miRGen.html), PicTar (http://pictar.mdc-berlin.
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de/), and miRBase (http://microrna.sanger.ac.uk/sequences/) 
computing for target predictions based on searches using Gene 
symbol DNMT3b (Entrez Gene ID 1789 and Ensembl Gene 
ID ENSG00000088305). Based on high stringency in silico 
selection criteria that included PicTar score (indicative of HMM 
maximum likelihood fit), highly conserved miRs, and good 
mirSVR scores (indicative of seed-site pairing, site context, free-
energy, and conservation), we identified 25 additional miRs that 
potentially target DNMT3b (Fig. 1). We prioritized the candidate 
miRs based on the available literature and/or their recognition 
as potential candidates by multiple target prediction programs 
(Fig. 1). miRs that were differentially expressed among breast 
cancer cells in primary tumors (23) and cell lines (31) were 
considered for further analysis. Based upon this computational 
analysis, we selected nine miRs for examination: miR-29a, 
miR-29b, miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, 
miR-203, and miR-222 (Fig. 1).
miR expression analysis was accomplished by real-time 
PCR utilizing an ABI 7500 real-time PCR System (Applied 
Biosystems, Foster City, CA) according to TaqMan miRNA 
assay protocol (Applied Biosystems). Total RNA samples (10 ng) 
were reverse transcribed using the TaqMan MiRNA Reverse 
Transcription Kit (Part no. 4366596 Applied Biosystems) 
and TaqMan miRNA specific primers (Applied Biosystems) 
according to the manufacturer's protocol. Real-time primers 
and probes for miR-29a (Assay ID 000412), miR-29b (Assay 
ID 000413), miR-29c (Assay ID 000415), miR-148a (Assay 
ID 000470), miR-148b (Assay ID 000471), miR-26a (Assay 
ID 000405), miR-26b (Assay ID 000407), miR-203 (Assay 
ID 000507), miR-222 (Assay ID 002276), and RNU66 (Assay 
ID 001002) were purchased from Applied Biosystems. These 
assays specifically detect mature miRNAs (not pre-miRNAs). 
All real-time PCR reactions were performed in triplicate using 
TaqMan Universal PCR Master Mix (Cat no. 4324018, Applied 
Biosystems) in 20 µl volume containing 10 µl TaqMan Universal 
PCR Master Mix, 1 µl of primers and probe mix of the miR-
specific TaqMan MicroRNA Assay (Applied Biosystems), 
1.33 µl of RT product, and 7.67 µl of nuclease free water and the 
following amplification conditions: 95˚C for 10 min, 40 cycles of 
95˚C for 15 sec and 60˚C for 1 min. Relative expression levels for 
each miR were calculated based upon the expression of RNU66 
and differences in gene expression were determined relative to 
MCF-12A using the comparative Ct method described in the 
ABI PRISM 7700 User Bulletin no. 2 (Applied Biosystems).
Gene expression analysis. Gene expression analysis was accom-
plished by real-time PCR utilizing an ABI 7500 Real-Time PCR 
System (Applied Biosystems). Total RNA samples (2 µg) were 
reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Part no. 4368814 Applied Biosystems) 
according to the manufacturer's protocol. Real-time primers and 
probes for CEACAM6 (Hs00366002_m1), CST6 (Hs00154599_
m1), DNMT3b (Hs00171876_m1), SCNN1A (Hs00168906_m1), 
and β-actin (Hs99999903_m1) were purchased from Applied 
Biosystems. All real-time PCR reactions were performed in 
triplicate using TaqMan Universal PCR Master Mix (Cat no. 
4324018, Applied Biosystems) in 20 µl volume (10 µl TaqMan 
Universal PCR Master Mix, 1.0 µl TaqMan Real-time primers 
and probes, and 9 µl cDNA and nuclease-free water) and the 
following amplification conditions: 95˚C for 10 min, 40 cycles of 
95˚C for 15 sec and 60˚C for 1 min. Relative expression levels for 
each gene were calculated based upon the expression of β-actin 
for each cell line and differences in gene expression were deter-
mined relative to MCF-12A using the comparative Ct method 
described in the ABI Prism 7700 User Bulletin no. 2 (Applied 
Biosystems).
DNMT3b protein expression in breast cancer cell lines. Cultured 
breast cancer cell lines, MCF12A (normal mammary epithelial 
cell line), and transfected cell lines (antagomir or pre-miR 
transfected) were lysed in phosphate buffered saline (137 mM 
NaCl, 2.7 mM KCl, 8 mM Na2PO4, 2 mM KH2PO4, pH 7.4) 
containing 0.1 mM phenylmethanesulphonylfluoride, 1 µg/ ml 
pepstain A, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM 
β-glycerol phosphate, 1 mM sodium orthovanadate, and 0.1% 
Triton X-100. Cell lysates were utilized for western blot analysis 
using standard methods. Protein concentrations were determined 
using the Bradford assay (Bio-Rad Quick Start Bradford, Cat 
no. 500-0205). Protein lysates (20-40 µg) were resolved on 
8% SDS-PAGE gels, followed by transfer onto polyvinylidene 
difluoride (PVDF) membranes (Cat no. 162-0184, Bio-Rad 
Sequi-Blot PVDF, 0.2 µM pore size, Millipore, Billerica, MA). 
PVDF membranes were blocked for 30 min in TBST (10 mM 
Tris-Cl, pH 7.6, 150 nM NaCl, 1% Tween-20) containing 5% 
milk, and then incubated with either anti-DNMT3b mouse mono-
clonal antibody (Cat no. IMG-184A Imgenex, San Diego, CA) 
diluted 1:5000 or anti-actin rabbit polyclonal antibody diluted 
1:10,000 (Cat no. sc-1616 Santa Cruz Biotechnology, Santa 
Cruz, CA) overnight in TBST containing 1% milk. Subsequently, 
membranes were washed with TBST 3 times for 5 min, and then 
incubated with a sheep anti-mouse (1:5000, Cat no. NA931 GE 
Healthcare, Piscataway, NJ) or donkey anti-rabbit (1:10,000, Cat 
no. NA934 GE Healthcare) horseradish peroxidase-conjugated 
secondary antibody in TBST containing 1% milk for 1 h at room 
temperature. The membranes were washed with TBST 3 times 
for 10 min each, and bound primary antibody was detected using 
ECL-Plus substrate (GE Healthcare).
Breast cancer cell line transfection with pre-miRs. Hyper-
methylator cell lines Hs578T, HCC1937, and SUM185 were 
selected for pre-miR transfection with miR-148b, miR-26b, and 
miR-29c. These cell lines exhibit DNMT hyperactivity, express 
DNMT3b at high levels (10), and exhibit negligible levels of 
expression of miR-26b, miR-29c, and miR-148b. All pre-miR 
transfections were performed in triplicate. Pre-miR miRNA 
precursors (miR-148b, PM10264; miR-26b, PM12899; miR-29c, 
PM10518) and standard control oligomers were obtained from 
Applied Biosystems. For optimization purposes, the Pre-miR 
miRNA Precursor Starter Kit (Applied Biosystems) was utilized 
for the reverse transfection procedure according to the manu-
facturer's protocol using siPORT NeoFX Transfection Agent 
(Part no. AM4510, Applied Biosystems). Four concentrations of 
transfection reagent (9, 12, 15 and 18 µl) were tested to obtain 
optimum conditions for pre-miR transfections for each cell 
line. Transfection reagent was diluted to 300 µl with opti-MEM 
(Gibco/Invitrogen Life Technologies), incubated for 10 min 
at room temperature, 24 µl of 6.25 nM of Pre-miR hsa-miR-1 
miRNA precursor or Pre-miR negative control no. 1 was diluted 
to 300 µl with opti-MEM for final concentration of 50 nM and 
gently mixed with diluted transfection agent before incubating 
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for 10 min at room temperature. The transfection complexes 
were dispensed into 6-well culture plates, and non-transfected 
controls were set up in parallel. Cells (2.4x105) were transferred 
in 2.4 ml of growth medium per well and incubated at recom-
mended growth conditions. After 24 h, the culture medium was 
replaced with fresh normal growth medium. Two days after 
transfection, total RNA was extracted from transfected and 
control cells. The expression level of PTK9 mRNA (target of 
pre-miR miR-1 miRNA precursor) was assessed by real-time 
PCR (Hs00702289_s1, Applied Biosystems) according to the 
manufacturer's instructions. Optimal transfection was observed 
with 12 µl transfection reagent in each cell line, producing 
75-90% reduction of PTK9 mRNA after transfection with 
Pre-miR miR-1. Hs578T, SUM185, and HCC1937 cells were 
transfected with pre-miR precursors for miR-148b, miR-26b and 
miR-29c employing the optimized conditions. After 48 h, total 
RNA was harvested for real-time PCR analysis for miR and gene 
expression analyses. In addition, transfected and control cells 
were lysed for western blot analysis (as described above).
Breast cancer cell line transfection with antagomirs. Non-hyper-
methylator cell lines BT20, MDA-MB-415, and MDA-MB-468 
were selected for antagomir transfection with miR-148b, 
miR-26b, and miR-29c. These cell lines have lower DNMT 
activity, express DNMT3b at low levels (10), and exhibit normal 
levels of expression of miR-26b, miR-29c, and miR-148b. All 
antagomir transfections were performed in triplicate. Anta-
gomirs (miR-148b, AM10264; miR-26b, AM12899; miR-29c, 
AM10518) and standard control oligomers were obtained from 
Applied Biosystems. For optimization of transfection conditions, 
the reverse transfection procedure was performed using four 
concentrations of transfection reagent (9, 12, 15 and 18 µl), 
as described for pre-miR transfections. Transfection reagent 
was diluted to 300 µl with opti-MEM (Gibco/Invitrogen Life 
Technologies), incubated for 10 min at room temperature, 
24 µl of 6.25 nM of Anti-miR let-7c miRNA inhibitor positive 
control or Anti-miR negative control no. 1 was diluted to 
300 µl with opti-MEM for final concentration of 50 nM and 
gently mixed with diluted transfection agent before incubating 
for 10 min at room temperature. Levels of HMGA2 mRNA 
(target of Anti-miR let-7c miRNA inhibitor positive control) 
were assessed by real-time PCR (Hs00171569_m1, Applied 
Biosystems) after RNA extraction. Optimal transfection was 
observed with 12 µl transfection reagent in each cell line, 
producing 1.8-to 2.4-fold increases in HMGA2 mRNA after 
transfection with Anti-miR let-7c miRNA inhibitor. BT20, 
MDA-MB-415, and MDA-MB-468 cells were transfected with 
antagomirs for miR-148b, miR-26b, and miR-29c, and after 
48 h, total RNA was harvested for real-time PCR analysis for 
miR and gene expression analyses. In addition, transfected and 
control cells were lysed for western blot analysis (as described 
above).
Statistical analysis. The values for the mean and standard error 
of the mean (SEM) were calculated using the statistical function 
of Microsoft Excel 2007. Statistical significance was determined 
Figure 1. miR regulators of DNMT3b mRNA. Schematic illustrating the selection and prioritization of miR regulators of DNMT3b for analysis. Several target 
prediction programs were utilized to predict miR interactions with DNMT3b. Criteria for filtering potential candidates are described in the schematic. In addition to 
selection of candidate miR regulators, known regulators of DNMT3b were identified from the literature. This selection strategy yielded nine miRs for examination: 
miR-29a, miR-29b, miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, miR-203, and miR-222.
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using an unpaired t-test (two-tailed). Error bars depicted in bar 
graphs represent SEM of 3-6 independent experiments.
Results
Hypermethylator breast cancer cell lines express diminished 
levels of regulatory miRs. Previous investigations identified a 
hypermethylation defect in a subset of breast cancer cell lines 
(10). Hypermethylator cell lines display DNMT hyperactivity 
and overexpression of DNMT3b, in contrast to non-hypermeth-
ylator cell lines (10). In the present study, we are investigating 
possible molecular mechanisms governing DNMT3b over-
expression in hypermethylator cell lines, with a focus on 
miR-mediated regulation of DNMT3b. Hence, we examined the 
levels of expression of select miRs that are known or predicted 
to regulate DNMT3b (miR-26a, miR-26b, miR-29a, miR-29b, 
miR-29c, miR-148a, miR-148b, miR-203, miR-222) among 
breast cancer cell lines that differentially express DNMT3b. 
Ten of these cell lines express the hypermethylation defect 
(BT-549, HS578T, HCC1937, MDA-MB-231, MDA-MB- 435S, 
MDA-MB-436, MDA-MB-453, SUM102, SUM149, SUM185) 
and six are non-hypermethylators (BT-20, MCF-7, MDA-MB-
415, MDA-MB-468, SK-BR-3, ZR-75-1) (10,32; unpublished 
data). Differential levels of miR expression were observed for 
six of the nine miRs evaluated, including miR-26a, miR-26b, 
miR-29c, miR-148a, miR-148b, and miR-203 (Fig. 2A). While 
there was variability in expression among the miRs examined, 
in general the hypermethylator cell lines expressed dimin-
ished levels compared to the non-hypermethylator cell lines 
(Fig. 2B-G). miR-29a, miR-29b, and miR-222 did not display 
the pattern of expression observed with the majority of miRs. 
miR-29a and miR-29b were expressed at similar levels among 
breast cancer cell lines irrespective of their methylation status. 
The lack of differential expression of these miRs is evident from 
a comparison of average levels in hypermethylator and non-
hypermethylator cell lines (Fig. 2A). In contrast to the pattern 
observed with other miRs, the average expression of miR-222 
among hypermethylator cell lines was higher than in non-hyper-
methylator cell lines. This is consistent with the suggestion that 
miR-222 functions as an oncogenic miR (33,34).
The average expression of miR-148a, miR-148b, miR-26a, 
and miR-26b among hypermethylator cell lines was significantly 
diminished compared to the average expression of these miRs 
among non-hypermethylator cell lines (p<0.05) (Fig. 2A). Ten/ten 
(100%) hypermethylator cell lines expressed low levels of miR-
148b, and 5/6 (83%) non-hypermethylator cell lines express higher 
levels of miR-148b (except BT20; Fig. 2D). Likewise, miR-148a is 
expressed at low levels in 9/10 (90%) hypermethylator cell lines 
(except MDA-MB-453) and the majority of non-hypermethylator 
cell lines (5/6, 83%) express miR-148a at higher levels (except 
MCF7; Fig. 2C). Eight/ten (80%) hypermethylator cell lines 
display low levels of miR-26a expression (except Hs578T and 
MDA-MB-453), whereas all non-hypermethylator cell lines (6/6, 
100%) express higher levels of miR-26a (Fig. 2E). Similarly, 9/10 
(90%) hypermethylator cell lines express low levels of miR-26b 
(except MDA-MB-453), and 5/6 (83%) non-hypermethylator cell 
lines express higher levels of miR-26b (except BT20; Fig. 2F). 
Differences in average expression of miR-29c and miR-203 in 
hypermethylator cell lines versus non-hypermethylator cell lines 
were not statistically significant (Fig. 2A), although there was a 
distinct trend towards lower expression in the hypermethylator 
cell lines (p=0.15 and p=0.19). Six/ten (60%) of hypermethylator 
cell lines expressed low levels of miR-29c (except MDA-MB-
231, MDA-MB-436, MDA-MB-453, and BT549) and 5/6 (83%) 
non-hypermethylator cell lines demonstrated higher levels of 
miR-29c (except MCF7; Fig. 2B). The expression of miR-203 
was low in both hypermethylator and non-hypermethylator cell 
lines, but with differential expression levels (Fig. 2G). Seven/
ten (70%) of hypermethylator cell lines expressed miR-203 at 
low or undetectable levels (except MDA-MB-453, SUM149, 
and HCC1937), while 5/6 (83%) non-hypermethylator cell lines 
expressed miR-203 at easily detectable levels (except SK-BR-3).
Diminished expression of miR-29c, miR-148a, miR-148b, 
miR-26a, miR-26b, and miR-203 predict hypermethylator 
status among breast cancer cell lines. We observed differential 
expression of miR-26a, miR-26b, miR-29c, miR-148a, miR-148b, 
and miR-203 among breast cancer cell lines with strong trends 
towards diminished expression in hypermethylators compared to 
non-hypermethylator cell lines (Fig. 2A). To evaluate the value of 
individual miR expression levels in the prediction of the methyla-
tion status of a given breast cancer cell line, a Bayesian analysis 
was performed. Threshold values were determined for each of 
the differentially expressed miRs using correct assignments 
(CA) as a guiding principle. These threshold values are indicated 
in Fig. 2B-G. The expression levels of five miRs emerged as 
excellent individual predictors of methylator status among breast 
cancer cell lines: miR-148b (CA 94%), miR-26b (CA 94%), 
miR-148a (CA 88%), miR-26a (88%), and miR-203 (CA 81%). 
These miRs individually displayed excellent sensitivity (range 
80-100%) and specificity (range 83-100%), as well as excellent 
positive predictive value (PPV range: 89-100%) and negative 
predictive value (NPV range 71-100%). The best threshold value 
for miR-29c produced CA 69% (sensitivity, 60%; specificity, 
83%; PPV, 86%; and NPV, 56%). The remaining miRs displayed 
poor predictive value for determination of methylation status of 
breast cancer cell lines.
miR expression patterns and miR scores for hypermethylator 
and non-hypermethylator breast cancer cell lines. Six regula-
tory miRs were chosen for further analysis based on excellent 
characteristics related to prediction of methylation status (CA, 
sensitivity, specificity, PPV, and NPV) among hypermethylator 
and non-hypermethylator breast cancer cell lines, including 
miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, and 
miR-203. miR scores were generated for each breast cancer 
cell line, reflecting the number of miRs with diminished 
expression. Hypermethylator breast cancer cell lines frequently 
express diminished levels of this panel of miRs. Nine/ten (90%) 
hypermethylator cell lines express >5 miRs at diminished 
levels (Fig. 3A), resulting in higher miR scores. The exception 
to this is MDA-MB-453, which expresses diminished levels 
of miR-148b only (Fig. 2D). Hence, MDA-MB-453 has a low 
miR score reflecting higher levels of expression of the majority 
of miRs examined (Fig. 3A). Three hypermethylator cell lines 
(MDA-MB-435s, SUM102, SUM185) express diminished levels 
of all six miRs examined (Fig. 3A). In contrast to the hypermeth-
ylator cell lines, non-hypermethylator cell lines typically express 
the majority of this panel of miRs at higher levels. Five/six (83%) 
of non-hypermethylator cell lines express ≥5 miRs at higher 
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Figure 2. Differential miR expression among hypermethylator and non-hypermethylator breast cancer cell lines. (A) White bars represent average miR expression 
among hypermethylator cell lines (n=10), and black bars represent average miR expression among non-hypermethylator cell lines (n=6). Comparison of the 
observed expression levels between hypermethylator cell lines and non-hypermethylator cell lines was accomplished using an unpaired t-test (two-tailed) and 
corresponding p-values are given (NS, not significant). (B-G) Analysis of miR expression levels among hypermethylator and non-hypermethylator breast cancer 
cell lines. Hypermethylator cell lines are represented by black bars and non-hypermethylator cell lines are represented by gray bars. The dashed line represents 
the optimal threshold value determined by Bayesian analysis for correct assignments related to the hypermethylator status of individual cell lines. Each real-time 
assay was performed in triplicate and error bars represent 15% SEM. MDA-MB-231, MDA-MB-415, MDA-MB-435s, MDA-MB-436, and MDA-MB-453 cell 
lines are designated 231, 415, 435s, 436, and 453, respectively; SUM102, SUM149, and SUM185 cell lines are represented as 102, 149, and 185, respectively; and 
HCC1937 is labeled 1937. (B) miR-29c expression, (C) miR-148a expression, (D) miR-148b expression, (E) miR-26a expression, (F) miR-26b expression and 
(G) miR-203 expression.
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levels (Fig. 3B), resulting in lower miR scores. The exception 
was MCF7, which expresses diminished levels of miR-29c and 
miR-148a (Fig. 2B and C). Three non-hypermethylator cell lines 
(MDA-MB-415, MDA-MB-468, ZR-75-1) expressed higher 
levels of all six miRs in this panel (Fig. 3B). Hypermethylator 
breast cancer cell lines exhibit an average miR score of 4.9±0.46, 
whereas, non-hypermethylator cell lines exhibit an average miR 
score of 0.67±0.33 (p<0.0001).
miR score correlates with gene expression score and promoter 
methylation score. A linear correlation analysis was performed 
to determine if miR score significantly associates with meth-
ylation score and expression score for each breast cancer cell 
line. Methylation score and expression score reflect the relative 
promoter methylation status (number of hypermethylated gene 
promoters) and the relative gene expression status (number 
of methylation-sensitive genes expressed), respectively, for 
methylation-sensitive biomarker genes associated with the 
hypermethylation defect (CEACAM6, CDH1, CST6, ESR1, 
GNA11, MUC1, MYB, TFF3 and SCNNIA) (10). A strong inverse 
correlation (r=-0.66, p=0.0056) was observed between miR 
score and gene expression score (Fig. 4A). Breast cancer cell 
lines that exhibit diminished expression of multiple regulatory 
miRs (high miR score) tend to express low levels of methyla-
tion-sensitive genes (gene expression score) and cell lines that 
express higher levels of regulatory miRs (low miR score) tend to 
express methylation-sensitive genes at higher levels (Fig. 4A). A 
strong correlation (r=0.72, p=0.002) was observed between miR 
score and methylation score (Fig. 4B). Breast cancer cell lines 
that exhibit diminished expression of multiple regulatory miRs 
(high miR score) exhibit higher methylation scores and cell lines 
that express higher levels of regulatory miRs (low miR score) 
tend to have lower methylation scores (Fig. 4B). Previous studies 
demonstrated significant relationships between overexpression 
of DNMT3b and gene expression scores and methylation scores 
for methylation-sensitive genes (10). The current results strongly 
Figure 3. miR expression patterns and miR scores for hypermethylator and 
non-hypermethylator breast cancer cell lines. Black boxes indicate a measured 
level of expression for an individual miR that is below the threshold value 
established through Bayesian analysis, and white boxes indicate a measured 
level of expression of an individual miR that is above the threshold value estab-
lished through Bayesian analysis. The numbers at the bottom of each column 
indicate the miR score, which represents a measure of the number of miRs 
expressed at diminished levels in an individual cell line. (A) miR expression 
patterns and miR scores for hypermethylator breast cancer cell lines. (B) miR 
expression patterns and miR scores for non-hypermethylator breast cancer cell 
lines.
Figure 4. miR expression patterns correlate with methylation-sensitive gene 
expression status and promoter methylation status among breast cancer cell lines. 
Correlation of miR expression patterns (miR score) with gene expression levels 
(based on RT-PCR) and promoter methylation status (based on methylation-
sensitive PCR) for methylation-sensitive genes among hypermethylator and 
non-hypermethylator breast cancer cell lines. Scores were calculated for differ-
entially expressed miRs (miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, and 
miR-203) and for well-characterized methylation sensitive genes (CEACAM6, 
CDH1, CST6, ESR1, GNA11, MUC1, MYB, TFF3, and SCNNIA). Methylation-
sensitive gene expression scores and promoter methylation scores were taken from 
previous studies (10). (A) Relationship between miR score and gene expression 
score among hypermethylator cell lines (open triangles) and non-hypermethylator 
cell lines (black squares). (B) Relationship between miR score and promoter 
methylation status among hypermethylator cell lines (open triangles) and non-
hypermethylator cell lines (black squares).
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support the suggestion that loss of miR expression may account 
for the DNMT3b-mediated hypermethylation defect among 
breast cancer cell lines that is characterized by methylation-
dependent loss expression of methylation-sensitive biomarker 
genes.
Co-regulation of miR expression in breast cancer cell lines. To 
determine if miRs that regulate DNMT3b are independently 
regulated or co-regulated at the level of expression, a linear 
correlation analysis was performed to examine patterns of miR 
expression among hypermethylator and non-hypermethylator 
breast cancer cell lines. Statistically significant linear relation-
ships were observed between the levels of expression of several 
miRs (Fig. 5A-F): miR-26a and miR-26b (r=0.92, p<0.0001), 
miR-148a and miR-26a (r=0.88, p<0.0001), miR-148a and 
miR-26b (r=0.85, p<0.0001), miR-29c and miR-148a (r=0.81, 
p=0.0002), miR-148a and miR-148b (r=0.83, p<0.0001), and 
miR-29c and miR-148b (r=0.92, p<0.0001). In addition, signifi-
cant linear relationships were observed for expression of miR-26a 
and miR-203 (r=0.71, p=0.0019), miR26b and miR-203 (r=0.68, 
p=0038), miR-26a and miR-29c (r=0.60, p=0.014), miR-148a and 
miR-203 (r=0.60, p=0.014), and miR-26b and miR-148b (r=0.5, 
p=0.04). No significant linear relationships were observed for 
expression of miR-26b and miR-29c, miR-148c and miR-203, or 
miR-29c and miR-203. Combined, these observations suggest 
that several miRs that function in the regulation of DNMT3b are 
co-regulated.
Changes in miR expression levels in hypermethylator and non-
hypermethylator breast cancer cell lines after pre-miR and 
antagomir transfection. To determine the mechanistic role of 
specific miRs in the dysregulation of DNMT3b among breast 
cancer cell lines, the complementary approach of modulating 
miR levels by transfection of pre-miR precursors (to enforce 
miR expression in cells lacking a given miR) or transfection of 
antagomirs (to knockdown miR expression in cells that express 
normal levels of a given miR) was employed. Transfection of 
hypermethylator cell lines Hs578T, HCC1937, and SUM185 
with pre-miR precursors for miR-148b, miR-26b, and miR-29c 
resulted in restoration of expression of these miRs (Fig. 6A-C). 
Following pre-miR transfection, Hs578T cells displayed 210-, 
160- and 240-fold increased levels of miR-148b, miR-26b and 
miR-29c (Fig. 6A). Likewise, pre-miR transfection produced 
430-, 2100- and 580-fold increases in miR-148b, miR-26b and 
miR-29c levels in HCC1937 cells (Fig. 6B), and 54,000-, 4,700-
and 2200-fold increases in miR-148b, miR-26b and miR-29c 
levels in SUM185 cells (Fig. 6C). Non-target control pre-miR 
precursors did not produce any significant increase in miR-148b, 
miR-26b and miR-29c levels in any of these cell lines (Fig. 6A-C).
Transfection of non-hypermethylator cell lines BT20, 
MDA-MB-415, and MDA-MB-468 with antagomirs directed 
against miR-148b, miR-26b and miR-29c resulted in a signifi-
cant knockdown of miR-148b, miR-26b and miR-29c levels 
(Fig. 6D-F). Antagomir transfection of BT20 cells resulted in 
reduction of miR-148b, miR-26b, and miR-29c levels by 76, 69 
and 73%, respectively (Fig. 6D). Likewise, antagomir transfection 
of MDA-MB-415 cells produced 76, 49 and 48% reductions in 
miR-148b, miR-26b, and miR-29c levels (Fig. 6E), and antagomir 
transfection of MDA-MB-468 cells resulted in 72, 69 and 35% 
reduction in miR-148b, miR-26b and miR-29c levels (Fig. 6F). 
Non-target control antagomirs did not produce significant altera-
tions in the level of miR-148b, miR-26b and miR-29c in any of 
these cell lines (Fig. 6D-F).
Perturbation of regulatory miR expression alters DNMT3b 
levels in hypermethylator and non-hypermethylator breast 
Figure 5. Co-regulation of miR expression among hypermethylator and non-hypermethylator breast cancer cell lines. Hypermethylator cell lines (closed squares) 
and non-hypermethylator cell lines (closed circles) demonstrate a statistically significant relationship between miR expression levels. The dashed line represents 
the linear regression trend line (p-values are indicated) for each relationship. (A) Association of expression between miR-26a and miR-26b. (B) Association of 
expression between miR-148a and miR-26a. (C) Association of expression between miR-148a and miR-26b. (D) Association of expression between miR-29c and 
miR-148a. (E) Association of expression between miR-148a and miR-148b. (F) Association of expression between miR-29c and miR-148b.
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cancer cell lines. Enforced expression of miR-148b, miR-26b 
and miR-29c in hypermethylator cell lines Hs578T, HCC1937 
and SUM185 resulted in statistically significant reduction in 
DNMT3b expression levels (Fig. 7A). In Hs578T cells, miR-29c 
expression reduced DNMT3b levels by 73%, and expression of 
miR-148b and miR-26b produced 62% reduction in DNMT3b 
levels (Fig. 7A). Similar results were obtained in HCC1937 
cells with 58-64% reductions of DNMT3b levels in response 
to enforced expression of miR-148b, miR-26b and miR-29c 
(Fig. 7A). The most dramatic effect of enforced pre-miR 
expression on DNMT3b levels was observed in SUM185 cells. 
Expression of miR-29c in SUM185 cells resulted in an 88% 
decrease in DNMT3b mRNA (Fig. 7A). Likewise, expression 
of miR-148b and miR-26b in SUM185 cells produced 80 and 
82% reduction in DNMT3b levels (Fig. 7A). Transfection of 
non-target control pre-miR precursors did not produce any 
significant change in DNMT3b levels in Hs578T, HCC1937 and 
SUM185 cells (Fig. 7A). Western blot analysis of cell lysates 
from Hs578T, HCC1937 and SUM185 cells following pre-miR 
transfection failed to detect significant alterations in DNMT3b 
protein levels (data not shown). However, the failure to detect 
changes in DNMT3b protein is likely due to the transient (48 h) 
nature of this assay system and the relatively long half-life of the 
DNMT3b protein. With persistent (stable) miR re-expression, 
we expect to see decreases in DNMT3b. Likewise, assessment 
of methylation-sensitive gene expression (for CEACAM6, CST6 
and SCNN1A) in Hs578T cells after enforced expression of 
miR-148b, miR-26b and miR-29c did not reveal changes in 
levels of expression compared to control cells (data not shown), 
consistent with the lack of change in DNMT3b protein levels. 
As above, with persistent (stable) miR re-expression, we expect 
to see alterations in methylation-sensitive gene expression coor-
dinate with changes in DNMT3b levels.
Antagomir-mediated knockdown of miR-148b, miR-26b 
and miR-29c in non-hypermethylator cell lines MDA-MB-468, 
MDA-MB-415 and BT20 resulted in statistically significant 
increases in DNMT3b expression levels (Fig. 7B). The most 
dramatic effects were observed in MDA-MB-468 cells, where 
miR-148b knockdown produced a 3.2-fold increase in DNMT3b 
mRNA, whereas knockdown of miR-26b and miR-29c resulted 
in 2-and 2.6-fold increases in DNMT3b levels, respectively 
(Fig. 7B). Comparable increases in DNMT3b expression levels 
(1.8-to 2-fold) were observed in BT20 cells following knock-
down of miR-148b, miR-26b and miR-29c (Fig. 7B). More 
modest increases of DNMT3b levels (1.2-to 1.4-fold) were 
observed in MDA-MB-415 cells after knockdown of miR-148b, 
miR-26b and miR-29c, but these alterations were statistically 
significant. Transfection of non-target control antagomirs did 
not produce any significant change in DNMT3b levels in these 
cell lines (Fig. 7B). Similar to the results obtained with pre-miR-
transfected hypermethylator cell lines, western blot analysis of 
cell lysates from MDA-MB-468, MDA-MB-415, and BT20 
cells following antagomir transfection failed to detect significant 
alterations in DNMT3b protein levels (data not shown). Failure to 
detect changes in DNMT3b protein is likely due to the transient 
(48 hour) nature of this assay system. With persistent (stable) 
miR knockdown, we expect to see increased DNMT3b levels. 
Further, assessment of methylation-sensitive gene expression (for 
CEACAM6, CST6 and SCNN1A) in MDA-MB-468 cells after 
antagomir-mediated knockdown of miR-148b, miR-26b and 
Figure 6. Changes in miR expression levels in hypermethylator and non-hypermethylator breast cancer cell lines after pre-miR and antagomir transfection. 
Speckled bars represent miR expression levels in untransfected control cells, black bars represent miR expression levels in cells transfected with non-target 
control oligomers, and crosshatched bars represent miR expression levels in cells after indicated pre-miR or antagomir transfections. (A) Hs578T breast cancer 
cells re-express miR-148b, miR-26b, and miR-29c after pre-miR transfection. (B) HCC1937 breast cancer cells re-express miR-148b, miR-26b, and miR-29c 
after pre-miR transfection. (C) SUM185 breast cancer cells re-express miR-148b, miR-26b, and miR-29c after pre-miR transfection. (D) BT20 breast cancer 
cells express diminished levels of miR-148b, miR-26b, and miR-29c after antagomir transfection. (E) MDA-MB-415 breast cancer cells express reduced levels of 
miR-148b, miR-26b, and miR-29c after antagomir transfection. (F) MDA-MB-468 breast cancer cells express reduced levels of miR-148b, miR-26b, and miR-29c 
after antagomir transfection. Each real-time assay was performed 3-6 times and error bars represent SEM. *p<0.05, **p<0.005 and ***p<0.0005, compared to 
untransfected control cells (unpaired t-test).
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miR-29c did not reveal changes in levels of expression compared 
to control cells (data not shown), consistent with the lack of 
change in DNMT3b protein levels in this short-term assay 
system. As above, with persistent (stable) miR knockdown, we 
expect to see alterations in methylation-sensitive gene expression 
coordinate with changes in the level of DNMT3b.
Discussion
Epigenetic changes significantly contribute to the normal 
regulation of gene expression and when dysregulated can 
significantly contribute to carcinogenesis (35,36). Aberrant 
epigenetic silencing of tumor suppressor genes and other nega-
tive mediators of cell proliferation has been documented in the 
development and progression of breast cancer (3,5,9). The CpG 
island methylator phenotype (or CIMP) represents a major 
epigenetic mechanism of colorectal carcinogenesis that has also 
been recognized in cancers affecting other tissues (37-39). We 
have identified a hypermethylation defect in a subset of human 
breast cancer cell lines and primary breast cancers that are char-
acterized by DNMT hyperactivity, overexpression of DNMT3b, 
and concurrent methylation-dependent silencing of numerous 
genes (including CDH1, CEACAM6, CST6, ESR1, GNA11, 
MYB, MUC1, SCNN1A and TFF) (10). Mining of microarray-
based expression data identified a strong cluster of primary breast 
cancers that display a gene expression signature associated with 
hypermethylation defect (10). A strong association was estab-
lished between the expression of the hypermethylation defect 
signature and the basal-like molecular subtype of breast cancers 
(10). Basal-like breast cancers are typically classified as triple-
negative, reflecting lack expression of estrogen and progesterone 
receptors (ER-/PR-), and absence of HER2 gene amplification 
(HER2-) (40,41). Hence, patients with basal-like breast cancer are 
not responsive to targeted therapies like tamoxifen (targeting ER) 
and trastuzumab (targeting HER2) (42,43). The poor prognosis 
associated with basal-like breast cancer and lack of druggable 
targets makes the fundamental observation of the co-segregation 
of the hypermethylation defect with basal-like breast cancer to 
be of utmost significance. Our observations suggest strongly that 
the DNA methylation machinery (and specifically DNMT3b) 
represents new/novel molecular target for development of drugs 
and treatment strategies for basal-like breast cancer.
In the present study, our goal was to elucidate the molecular 
mechanism accounting for overexpression of DNMT3b in hyper-
methylator breast cancer cell lines. Recent studies link miRs 
to the post-transcriptional regulation DNMT3b expression in 
various tissues. Loss of expression of members of miR-29 family 
and overexpression of DNMT3b has been shown in lung cancer 
(26) and acute myeloid leukemia (27). Likewise, there is evidence 
supporting the negative regulation of DNMT3b by miR-148a and 
miR-148b in cell lines of multiple origins (28). The results of the 
present study strongly suggest that loss of regulatory miR expres-
sion contributes to DNMT3b overexpression in hypermethylator 
breast cancer cell lines. This evidence includes: i) differential 
expression of regulatory miRs between hypermethylator and 
non-hypermethylator cell lines, ii) significantly diminished 
expression of miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, 
and miR-203 among hypermethylator breast cancer cell lines, 
iii) pre-miR-mediated re-expression of miR-148b, miR-26b, or 
miR-29c in hypermethylator breast cancer cell lines (Hs578T, 
HCC1937 and SUM185) reduces DNMT3b mRNA levels, and 
iv) antagomir-mediated knockdown of miR-148b, miR-26b, 
or miR-29c in non-hypermethylator breast cancer cell lines 
(MDA-MB-468, MDA-MB-415, and BT20) leads to increased 
DNMT3b mRNA levels. The observed loss of regulatory miRs 
in expression of the pro-cancerogenic hypermethylation defect 
suggests that these miRs possess a tumor suppressor-like func-
tion in breast, similar to other tissues (26-28).
miRs are predicted to post-transcriptionally regulate more 
that 60% of all protein-encoding genes in mammals and 
contribute to almost every cellular process, normal and patho-
logical (44). miRs have been recently been established as key 
players in carcinogenesis, with functions that can be oncogenic 
or tumor suppressor-like (15). Our results suggest loss of combi-
nations of miR-29c, miR-148a, miR-148b, miR-26a, miR-26b 
and miR-203 is associated with expression of the hypermethyl-
ation defect in breast cancer cell lines, consistent with the idea 
that these miRs function as negative mediators of the neoplastic 
phenotype. Diminished levels of these miRs have been docu-
mented in various forms of cancer, supporting the suggestion 
that these miRs possess tumor suppressor-like function. Reduced 
expression of miR-26a occurs in hepatocellular carcinoma, oral 
Figure 7. Perturbation of regulatory miR expression affects DNMT3b 
levels in hypermethylator and non-hypermethylator breast cancer cell lines. 
(A) Hypermethylator breast cancer cells (Hs578T, HCC1937, and SUM185) 
exhibit significant reduction in DNMT3b mRNA levels following pre-miR 
transfection for miR-148b, miR-26b, and miR-29c. (B) Non-hypermethylator 
breast cancer cells (MDA-MB-468, MDA-MB-415, and BT20) display signifi-
cantly increased DNMT3b mRNA levels following transfection with antagomirs 
for miR-148b, miR-26b, and miR-29c. Each real-time assay was performed 
3-6 times and error bars represent SEM. **p<0.005, ***p<0.0005, compared to 
untransfected control cells (unpaired t-test).
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squamous cell carcinoma, bladder cancer, thyroid anaplastic 
carcinoma, Burkitt's lymphoma, acute myeloid leukemia, papil-
lary carcinoma, prostate cancer, and breast cancer (44-46). 
miR-26b expression is diminished in Hodgkin's lymphoma, oral 
squamous cell carcinoma, and prostate cancers (46). miR-29c 
expression is depressed in nasopharyngeal carcinomas, bladder 
tumors, chronic lymphocytic leukemia, acute myeloid leukemia, 
lung cancers, cholangiocarcinoma, esophageal squamous cell 
carcinoma, and pancreatic ductal adenocarcinoma (44-48). 
miR-148a is down-regulated in breast cancers, papillary thyroid 
carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, 
and colorectal adenocarcinoma (45,46). miR-148b is expressed 
at reduced levels in oral squamous cell carcinoma, papillary 
thyroid carcinoma, prostate cancer, colorectal adenocarcinoma, 
and pancreatic ductal adenocarcinoma (46). miR-203 levels are 
diminished in oral squamous cell carcinoma, chronic myeloid 
leukemia, hepatocellular adenomas, and esophageal squamous 
cell carcinoma (45,46). These studies from the literature docu-
ment loss or diminished expression of miR-29c, miR-148a, 
miR-148b, miR-26a, miR-26b, and miR-203 in various forms of 
cancer, including breast in some cases.
Several molecular mechanisms contribute to miR dysregu-
lation in cancer, including genetic abnormalities (such as 
chromosomal rearrangement, deletion, amplification, or sequence 
mutations) and epigenetic changes (methylation-dependent 
silencing of miR expression or alterations in the miRNA biogen-
esis machinery) (44). Numerous miR genes (more than 50%) are 
positioned within or close to chromosomal fragile sites and other 
genomic regions associated with cancer (44). Genetic alterations 
involving these chromosomal regions result in dramatic altera-
tion of miR expression levels (44). Likewise, numerous studies 
report promoter hypermethylation as an important mechanism 
leading to loss of miR expression in cancer (15). Loss of miR-203 
expression is associated with fragile site on chromosome, 14q32 
(49), as well as through promoter hypermethylation in hemato-
poietic malignancies (49,50). miR-148a and miR148b are also 
susceptible to methylation-dependent silencing in cancer (15). 
We found miR-203 to be significantly co-regulated with miR148a 
and miR-148b, suggesting the possibility of a common epigenetic 
mechanism accounting for their diminished expression in hyper-
methylator cell lines. These examples from the literature suggest 
that loss of regulatory miR expression leading to DNMT3b 
dysregulation could be the result of genetic or epigenetic mecha-
nisms. Given the linkage between basal-like breast cancers and 
expression of the hypermethylation defect, loss of regulatory miR 
expression leading to DNMT3b overexpression may represent a 
very early and significant molecular alteration during the natural 
history of breast carcinogenesis. Further, loss of regulatory miR 
expression and establishment of the hypermethylation defect 
(with DNMT3b overexpression) may determine and/or drive the 
basal-like molecular subtype of breast cancer.
The purpose of this study was to elucidate the molecular 
mechanism governing the overexpression of DNMT3b associ-
ated with the expression of hypermethylation defect in breast 
cancer. The results of this study strongly suggest that multiple 
miRs post-transcriptionally regulate DNMT3b in combination 
and that loss of expression of these regulatory miRs contributes 
to DNMT3b overexpression. Mechanistic dissection of the role 
of selected miRs in the regulation of DNMT3b among hyper-
methylator and non-hypermethylator breast cancer cell lines 
produced additional evidence for the importance of this molec-
ular regulating network in determination of the methylation 
status of breast cancer cell lines. Re-expression of regulatory 
miRs reduces DNMT3b mRNA levels in hypermethylator 
breast cancer cell lines, and down-regulation of regulatory 
miRs increases DNMT3b mRNA levels in non-hypermethylator 
breast cancer cell lines.
In conclusion, the molecular mechanism governing the 
DNMT3b-mediated hypermethylation defect in breast cancer 
cell lines involves the loss of post-transcriptional regulation of 
DNMT3b by regulatory miRs.
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